INTRODUCTION
Timely pre-exposure prophylaxis (PrEP) initiation is critical in at-risk populations, given that HIV acquisition risk persists during delays. In PROUD, a pragmatic trial that randomized participants to immediate or delayed PrEP, HIV incidence in the delayed arm was 9 per 100 person-years compared with 1 in the immediate group. 1 Patients who ask to initiate PrEP may do so at times of elevated HIV risk. 2 Furthermore, factors motivating providers to offer PrEP, such as diagnosis of a sexually transmitted infection, reflect proximate HIV risk. 3 Delays in PrEP initiation should be avoided because they represent missed opportunities to prevent HIV acquisition during risk intervals.
Initiating PrEP quickly may have indirect benefits that encourage PrEP persistence (staying on PrEP) as has been seen in HIV treatment. [4] [5] [6] [7] Individuals who have streamlined PrEP initiation may experience enhanced self-efficacy, encouraging continued engagement. 8, 9 Furthermore, individuals with delayed initiation may experience "temporal discounting," a behavioral economics concept that describes the tendency to discount benefits in the future compared with the present, particularly when the future benefit requires overcoming immediate barriers. 10 Panel management is a population-based care approach that proactively focuses on the health of the population of patients assigned to a clinic. We previously found that panel management interventions were associated with greater completion of PrEP laboratory monitoring. 11 We examined factors associated with earlier PrEP initiation in a safety-net health care system of 15 clinics, the San Francisco Public Health Primary Care Clinics (SFPCC). We hypothesized that initiating PrEP with panel management/patient navigationwhich uses a PrEP registry to generate visit reminders, allows for standing laboratory orders, and provides access to a navigator-would be associated with earlier PrEP initiation. As a secondary outcome, we measured if delays in PrEP initiation .30 days in the SFPCC were associated with shorter PrEP persistence.
METHODS
We analyzed data for patients who were prescribed PrEP in the SFPCC from July 1, 2012, to July 31, 2017 (n = 411). We could not capture individuals who were interested but were not prescribed PrEP. We obtained demographic, visit data, and PrEP prescriptions through chart abstraction and e-prescription databases. PrEP indication was classified by the following descending hierarchy: serodifferent relationship, men who have sex with men, transgender women who have sex with men, people who inject drugs, or at-risk heterosexual. A panel management/patient navigation intervention, initiated in 2015 in 4 of 15 clinics in response to seroconversions at higher-volume PrEP clinics, included creating PrEP patient registries using a shared spreadsheet, routinizing follow-up/laboratory reminders, making a pharmacist available for follow-up visits, and providing patient navigators for both in-person and text messaging (SMS) assistance. The navigators set a goal of ,72 hours for PrEP initiation, or 1 week if there were insurance or other barriers.
We determined the date of initial PrEP discussion by reviewing all visits in this cohort in which PrEP or HIV prevention medication was discussed. We collected PrEP start/ stop dates as documented by the provider. For the fewer than 20% of records in which a start date was not available, we used the date a PrEP prescription was sent. The primary outcome was time from first documented PrEP discussion to initiation. We used time to PrEP initiation rather than time to PrEP prescription to best approximate the at-risk period in which the patient requested or the provider recommended PrEP but PrEP was not yet of benefit. As a secondary outcome, we assessed PrEP persistence defined by time between PrEP start/stop dates, with discontinuation defined as .90 days without restarting PrEP. For the less than one-fifth of records in which a stop date was unavailable, discontinuation was defined as 90 days not covered by an active prescription including refills.
Using a Cox proportional-hazards model, we evaluated the association of factors including demographics, PrEP indication, provider panel size, total prescription duration (eg, 30 pills with 3 refills was coded as .90 days), year, and insurance status, with time from PrEP discussion to initiation. The panel management/navigation variable was coded at the clinic level as a time-dependent covariate, based on when the program started at each clinic. Hazard ratios (HRs) greater than 1 indicate earlier PrEP initiation. We tested for violations of the proportional-hazards assumption by examining correlation between time and scaled Schoenfeld residuals.
To explore incomplete documentation of PrEP initiation date's effect on the outcome of delayed initiation, we performed a sensitivity analysis using an alternate outcome of time from PrEP discussion to first prescription. We performed a second sensitivity analysis controlling for clinic sites receiving the panel management intervention to explore whether clinic-related factors besides the intervention could account for the relationship between panel management and time to PrEP initiation. As a final sensitivity analysis, we reestimated the primary model substituting indicators for each PrEP indication (allowing more than one to be positive) for the original hierarchical classification.
To evaluate the impact of delayed PrEP initiation (defined as .30 days in this specific analysis) on later PrEP persistence, we used a Cox proportional-hazards model, controlling for patient age, sex at birth, race/ethnicity, PrEP indication, year of initiation, and total PrEP prescription duration, including refills.
RESULTS
During the study period, 411 patients across SFPCC received PrEP. Most (85%) were male sex at birth, with a median age of 34 years ( Table 1 ). The cohort was racially/ ethnically diverse: 13% were African American, 8% Asian, 27% Latino, 17% other, and 36% white. Overall, 16% had a primary PrEP indication of serodifferent relationship, 65% as men who have sex with men, 1% people who inject drugs, (Table 1) . Navigators estimated that all PrEP initiators in the postintervention intervals received some component of the intervention, and no SFPCC PrEP users were missing from the PrEP registries. There were 3 HIV seroconversions among the 411: one prescribed but who had not yet started taking PrEP due to concerns about side effects, the second was using intermittent PrEP at nonrecommended frequencies, and the third had discontinued PrEP due to selfperceived low risk.
Delays in PrEP Initiation
Median time from documented PrEP discussion to initiation was 7 days. However, a substantial minority of individuals experienced delayed PrEP initiation. Overall, 29% waited .30 days to initiate PrEP and 12% waited .90 days (Fig. 1) . Reasons for delay .30 days included: 49% provider [ie, delaying to review laboratory test results/adherence at future visits or deferring to the primary care provider]; 33% patient factors or concerns (including 12% no show visits, 10% concern if at risk, 9% concern about side effects); and 18% insurance or pharmacy issues.
The only factor associated with earlier PrEP initiation in the adjusted model was panel management/navigation [HR: 1.5; 95% confidence interval (95% CI): 1.1 to 2.0], whereas other race/ethnicity was associated with later PrEP initiation (HR: 0.7; 95% CI: 0.5 to 1.0), with a trend toward later PrEP initiation in African Americans (HR 0.8; 95% CI: 0.5 to 1.0; both vs. white race; Table 1 ). The association of panel management/patient navigation with earlier PrEP initiation did not differ among subgroups of race/ethnicity (overall heterogeneity P = 0.17).
Overall, median PrEP persistence was 6 months. In adjusted models, PrEP initiation delays .30 days were associated with higher PrEP discontinuation (HR: 1.3; 95% CI: 1.0 to 1.7).
In our first sensitivity analysis using time to PrEP prescription rather than documented PrEP initiation date, the median time to PrEP prescription was 6 days, and the estimated effect of panel management was slightly stronger (HR: 1.6; 95% CI: 1.2 to 2.1); results were otherwise unchanged. The second analysis revealed no confounding of panel management/navigation's effect by fixed characteristics of the 4 sites that introduced it (HR remained 1.5; 95% CI: 1.1 to 2.2). In the third sensitivity analysis that allowed multiple PrEP indications rather than a hierarchy, the effect of panel management did not change (HR: 1.5; 95% CI: 1.1 to 2.0).
DISCUSSIONS
In a diverse sample of 411 PrEP users at 15 clinics within an urban safety-net system, the median delay to PrEP initiation was 1 week. Given the challenges around access that publicly insured and uninsured individuals face, this achievement is remarkable. Our data indicate that even within the primary care safety-net, PrEP initiation in a week is feasible, a time frame that should be emulated in other settings.
Despite this achievement, nearly a third of patients waited .30 days to start PrEP, with 12% waiting .90 days. Patients with delayed PrEP initiation may be at risk of HIV infection, and, indeed, one SFPCC client seroconverted during delayed PrEP initiation. 1 Although we observed a trend toward delayed PrEP initiation among African Americans, this was not statistically significant in the adjusted model, and the mechanism of delay in those with other race/ethnicity is unclear. Outcomes in PrEP users should be examined by race/ethnicity, given observed disparities in PrEP uptake among African Americans in other studies. 12 Approximately one-third of delays were related to patient concerns or contemplation. Providers must navigate tensions between respect for patient autonomy vs. expedient initiation based on the known efficacy and safety of PrEP. This period of patient doubt has been termed "PrEP contemplation without initiation," and may be amenable to provider or navigator counseling or other interventions. 13 Finally, the majority of delays were related to systems issues, including waiting for a follow-up visit to review laboratory test results, deferring PrEP initiation to the primary care provider, or prior authorization or coverage gaps. Because patient willingness to initiate PrEP may wax and wane over time, we should take advantage of opportunities to initiate PrEP when patient interest is high and provide mechanisms to address visit availability, insurance, pharmacy issues, or patient concerns expeditiously. 13 Panel management approaches to PrEP delivery have been implemented in specialty PrEP programs and sexually transmitted disease clinics. [14] [15] [16] Our analysis is the first to examine factors associated with PrEP initiation in a realworld setting and to identify that a panel management/patient navigation program is associated with earlier PrEP initiation. Panel management/patient navigation may have led to earlier PrEP initiation by addressing insurance barriers, providing automatic reminders to providers to send PrEP prescriptions, and responding to patient concerns expeditiously by SMS messaging with navigators. Panel management approaches may be well suited to PrEP rollout in primary care settings where PrEP experience among providers may vary. 17 Recent and ongoing HIV research has supported rapid antiretroviral initiation, given high acceptance, improved care retention, and increased rates of viral suppression, with community prevention benefits. [4] [5] [6] [7] Analogously, setting a goal of PrEP initiation within a week can decrease HIV risk intervals, and may facilitate PrEP persistence, although this association requires additional study. Use of same-day HIV testing and follow-up of initial laboratory test results, support of navigators to negotiate insurance and other barriers, and using panel management staff to identify missing laboratory test results, prescriptions, or follow-up visits could facilitate this approach. Rapid fourth-generation HIV testing and pointof-care creatinine and hepatitis B surface antigen testing could allow for provision of the first dose of PrEP on the day of discussion. 18 Health systems should track delayed initiation, which could be automated using ICD-10 codes and structured medical record fields, to identify disparities in initiation time by subgroup and areas for improvement.
Limitations of the study include inability to analyze undocumented data or to distinguish which components of the panel management/navigation intervention were associated with earlier initiation. Moreover, our data have limited generalizability to populations not within a primary care, safety-net setting in a Medicaid expansion state. Although it is possible that we underestimated time to PrEP initiation due to incomplete documentation, we would predict that incomplete documentation on average would bias panel management/navigation's association with earlier PrEP initiation toward the null, given the fact that PrEP users who received the intervention had increased health care contact and PrEP documentation.
Although we identified delays in PrEP initiation in a minority of PrEP users in a safety-net primary care clinic system, the median time to PrEP initiation in a diverse population was just 1 week. Moreover, our data suggest that PrEP panel management/navigation could assist the near one-third of our sample who experienced delays of more than a month. Interventions that reduce delays in PrEP initiation are critical because they can potentially reduce HIV seroconversion risk. Further research should examine whether same-day or early PrEP initiation, potentially with the support of panel management and patient navigation, could improve PrEP outcomes such as adherence and persistence in a randomized clinical trial.
